Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Eukaryotic Gene Expression
IF: 2.156 5-Year IF: 2.255 SJR: 0.649 SNIP: 0.599 CiteScore™: 3

ISSN Print: 1045-4403
ISSN Online: 2162-6502

Critical Reviews™ in Eukaryotic Gene Expression

DOI: 10.1615/CritRevEukaryotGeneExpr.2017019712
pages 229-236

Role of Interleukin-6 in Development of Insulin Resistance and Type 2 Diabetes Mellitus

Kanwal Rehman
Department of Pharmacy, University of Agriculture, Faisalabad, Pakistan
Muhammad Sajid Hamid Akash
Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan
Aamira Liaqat
Department of Pharmaceutical Chemistry, Government College University Faisalabad, Pakistan; Department of Biochemistry, Government College University Faisalabad, Pakistan
Shagufta Kamal
Department of Biochemistry, Government College University Faisalabad, Pakistan
Muhammad Imran Qadir
Institute of Molecular Biology and Biotechnology, Bahauddin Zakariya University, Multan, Pakistan
Akhtar Rasul
Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan

ABSTRACT

Interleukin-6 (IL-6) is a proinflammatory cytokine that decisively induces the development of insulin resistance and pathogenesis of type 2 diabetes mellitus (T2DM) through the generation of inflammation by controlling differentiation, migration, proliferation, and cell apoptosis. The presence of IL-6 in tissues is a normal consequence, but its irregular production and long-term exposure leads to the development of inflammation, which induces insulin resistance and overt T2DM. There is a mechanistic relationship between the stimulation of IL-6 and insulin resistance. IL-6 causes insulin resistance by impairing the phosphorylation of insulin receptor and insulin receptor substrate-1 by inducing the expression of SOCS-3, a potential inhibitor of insulin signaling. In this article, we have briefly described how IL-6 induces the insulin resistance and pathogenesis of T2DM. The prevention of inflammatory disorders by blocking IL-6 and IL-6 signaling may be an effective strategy for the treatment of insulin resistance and T2DM.


Articles with similar content:

Determinants of Pathologic Mineralization
Critical Reviews™ in Eukaryotic Gene Expression, Vol.18, 2008, issue 1
Thorsten Kirsch
Macrophage Polarization: Implications on Metabolic Diseases and the Role of Exercise
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 2
Loreana Sanches Silveira, Barbara de Moura Mello Antunes, José Cesar Rosa Neto, Ronaldo Vagner Thomatieli dos Santos, Fábio Santos Lira, Andre Luis Araujo Minari
Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Critical Reviews™ in Oncogenesis, Vol.21, 2016, issue 1-2
Mark C. Kelley
Mechanisms Behind the Anti-inflammatory Actions of Insulin
Critical Reviews™ in Immunology, Vol.31, 2011, issue 4
Morley D. Hollenberg, Eric Hyun, Rithwik Ramachandran, Nathalie Vergnolle
Cancer Stem Cells, Their Microenvironment and Anoikis
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 1
Sercin Karahüseyinogluc, Sule Ayla